Skip to main content
SpringerLink
Log in

Could we apply the criteria of DAWN and DEFUSE-3 trials for slow progressors, beyond 24 h?

  • Letter to the Editor
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Goyal M, Menon BK, van Zwam WH et al (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 23:1723–1731. https://doi.org/10.1016/S0140-6736(16)00163-X

    Article  Google Scholar 

  2. Pereira VM, Mehta BP, Baxter BW et al (2018) Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378:11–21. https://doi.org/10.1056/NEJMoa1706442

    Article  PubMed  Google Scholar 

  3. Albers GW, Marks MP, Kemp S et al (2018) Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 378:708–718. https://doi.org/10.1056/NEJMoa1713973

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rocha M, Jovin TG (2017) Fast versus slow progressors of infarct growth in large vessel occlusion stroke: clinical and research implications. Stroke 48:2621–2627. https://doi.org/10.1161/STROKEAHA.117.017673

    Article  PubMed  Google Scholar 

  5. Desai SM, Haussen DC, Aghaebrahim A et al (2018) (2018) Thrombectomy 24 hours after stroke: beyond DAWN. J Neurointervention Surg 10:1039–1042. https://doi.org/10.1136/neurintsurg-2018-013923

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interventional Neuroradiology Department, Fondation Ophtalmologique Adolphe de Rothschild, Rue Manin 25, 75019, Paris, France

    François Delvoye, Jean-Philippe Desilles & Mikael Mazighi

  2. Laboratory of Vascular Translational Science, U1148 INSERM, Université de Paris, Paris, France

    Jean-Philippe Desilles & Mikael Mazighi

Authors
  1. François Delvoye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Philippe Desilles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mikael Mazighi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Delvoye.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and waived the need for informed patient consent (CE_20181218_5_JDS).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Delvoye, F., Desilles, JP. & Mazighi, M. Could we apply the criteria of DAWN and DEFUSE-3 trials for slow progressors, beyond 24 h?. Acta Neurol Belg 120, 977–980 (2020). https://doi.org/10.1007/s13760-020-01277-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-020-01277-7

Keywords

Search

Navigation